Q1 2024 EPS Estimates for Balchem Co. (NASDAQ:BCPC) Lowered by Sidoti Csr

Balchem Co. (NASDAQ:BCPC) – Research analysts at Sidoti Csr dropped their Q1 2024 earnings per share estimates for shares of Balchem in a research note issued to investors on Wednesday, April 24th. Sidoti Csr analyst K. May now forecasts that the basic materials company will post earnings of $0.98 per share for the quarter, down from their prior estimate of $1.00. The consensus estimate for Balchem’s current full-year earnings is $4.14 per share. Sidoti Csr also issued estimates for Balchem’s Q2 2024 earnings at $1.00 EPS, Q3 2024 earnings at $1.06 EPS, Q4 2024 earnings at $1.06 EPS, FY2024 earnings at $4.10 EPS, Q1 2025 earnings at $1.09 EPS, Q2 2025 earnings at $1.12 EPS, Q3 2025 earnings at $1.19 EPS, Q4 2025 earnings at $1.18 EPS and FY2025 earnings at $4.59 EPS.

Separately, StockNews.com lowered Balchem from a “buy” rating to a “hold” rating in a research report on Thursday.

Balchem Trading Up 0.5 %

BCPC opened at $139.26 on Friday. The business has a 50 day simple moving average of $152.25 and a two-hundred day simple moving average of $139.84. The firm has a market capitalization of $4.49 billion, a price-to-earnings ratio of 41.34, a PEG ratio of 4.25 and a beta of 0.71. The company has a debt-to-equity ratio of 0.31, a current ratio of 2.12 and a quick ratio of 1.38. Balchem has a one year low of $110.74 and a one year high of $159.52.

Balchem (NASDAQ:BCPC) last released its quarterly earnings results on Friday, February 16th. The basic materials company reported $0.95 EPS for the quarter, beating analysts’ consensus estimates of $0.93 by $0.02. The business had revenue of $228.70 million during the quarter, compared to analyst estimates of $234.66 million. Balchem had a return on equity of 10.69% and a net margin of 11.77%. Balchem’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.66 EPS.

Institutional Trading of Balchem

Several hedge funds and other institutional investors have recently made changes to their positions in BCPC. Signaturefd LLC boosted its stake in Balchem by 123.0% during the 4th quarter. Signaturefd LLC now owns 165 shares of the basic materials company’s stock valued at $25,000 after purchasing an additional 91 shares during the last quarter. Principal Securities Inc. purchased a new stake in Balchem during the 4th quarter valued at $28,000. Operose Advisors LLC purchased a new stake in Balchem during the 3rd quarter valued at $31,000. GAMMA Investing LLC purchased a new stake in Balchem during the 4th quarter valued at $56,000. Finally, YHB Investment Advisors Inc. purchased a new stake in Balchem during the 1st quarter valued at $69,000. Hedge funds and other institutional investors own 87.91% of the company’s stock.

Insider Transactions at Balchem

In related news, SVP Michael Robert Sestrick sold 11,100 shares of the company’s stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $153.21, for a total value of $1,700,631.00. Following the sale, the senior vice president now owns 6,736 shares in the company, valued at approximately $1,032,022.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, SVP Michael Robert Sestrick sold 11,100 shares of the company’s stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $153.21, for a total value of $1,700,631.00. Following the sale, the senior vice president now owns 6,736 shares in the company, valued at approximately $1,032,022.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Theodore L. Harris sold 34,350 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $154.29, for a total value of $5,299,861.50. Following the completion of the sale, the chief executive officer now owns 66,412 shares in the company, valued at approximately $10,246,707.48. The disclosure for this sale can be found here. In the last quarter, insiders sold 76,630 shares of company stock valued at $11,843,249. Corporate insiders own 1.77% of the company’s stock.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.